Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q2619971> ?p ?o }
Showing triples 1 to 41 of
41
with 100 triples per page.
- Q2619971 subject Q8395794.
- Q2619971 subject Q8529504.
- Q2619971 subject Q9688903.
- Q2619971 abstract "Fibrinolysin is an enzyme derived from plasma of bovine origin or extracted from cultures of certain bacteria. It is used locally only and exclusively together with the enzyme desoxyribonuclease (extracted from bovine pancreas). Fibrinolysin and desoxyribonuclease both act as lytic enzymes. The combination is available as ointment containing 1 BU (Biological Unit) fibrinolysin and 666 BUs desoxyribonuclease per gram.Fibrinolysin attacks and inactivates fibrin molecules occurring in undesirable exudates on the surface of the human body and on human mucosa, e.g., in superficial wounds and burns, while desoxyribonuclease targets and destroys (human) DNA. The combination of the two enzymes has a synergistic effect on necrotic but not on living tissue. According to the manufacturer the ointment provides enhanced wound cleaning and accelerates the healing process.Both enzymes are marginally resorbed into systemic circulation because of their very high molecular weight and their macromolecular structure.The activity of both enzymes is almost completely exhausted after 24 hours. Usually, it is necessary to repeat the application (and renew the dressing) every 6 to 8 hours until healing becomes complete.The ointment is marketed by Pfizer under the brand name Fibrolan in a variety of countries (e.g. Switzerland). It is currently not approved in the USA.Where approved, Fibrolan has been licensed on the basis of claimed good therapeutical experience, but adequate and well controlled studies are still lacking.In the past, combinations with the antibiotic chloramphenicol were available, but because chloramphenicol in any form of application has led to aplastic anemia and death, these were banned. Additionally, combinations with the antifibrinolytic agent tranexamic acid have been withdrawn from pharmaceutic markets.".
- Q2619971 atcPrefix "B01".
- Q2619971 atcSuffix "AD05".
- Q2619971 casNumber "9001-90-5".
- Q2619971 drugbank "DB08977".
- Q2619971 fdaUniiCode "A4028U842W".
- Q2619971 wikiPageWikiLink Q10876.
- Q2619971 wikiPageWikiLink Q1139400.
- Q2619971 wikiPageWikiLink Q1219805.
- Q2619971 wikiPageWikiLink Q1573613.
- Q2619971 wikiPageWikiLink Q170518.
- Q2619971 wikiPageWikiLink Q184753.
- Q2619971 wikiPageWikiLink Q206921.
- Q2619971 wikiPageWikiLink Q215118.
- Q2619971 wikiPageWikiLink Q27205.
- Q2619971 wikiPageWikiLink Q274515.
- Q2619971 wikiPageWikiLink Q40397.
- Q2619971 wikiPageWikiLink Q418666.
- Q2619971 wikiPageWikiLink Q468787.
- Q2619971 wikiPageWikiLink Q4979192.
- Q2619971 wikiPageWikiLink Q5958765.
- Q2619971 wikiPageWikiLink Q7430.
- Q2619971 wikiPageWikiLink Q8395794.
- Q2619971 wikiPageWikiLink Q846316.
- Q2619971 wikiPageWikiLink Q8529504.
- Q2619971 wikiPageWikiLink Q9688903.
- Q2619971 atcPrefix "B01".
- Q2619971 atcSuffix "AD05".
- Q2619971 casNumber "9001".
- Q2619971 drugbank "DB08977".
- Q2619971 unii "A4028U842W".
- Q2619971 type ChemicalSubstance.
- Q2619971 type Drug.
- Q2619971 type ChemicalObject.
- Q2619971 type Thing.
- Q2619971 type Q8386.
- Q2619971 comment "Fibrinolysin is an enzyme derived from plasma of bovine origin or extracted from cultures of certain bacteria. It is used locally only and exclusively together with the enzyme desoxyribonuclease (extracted from bovine pancreas). Fibrinolysin and desoxyribonuclease both act as lytic enzymes.".
- Q2619971 label "Fibrinolysin".